Our mission is to transform scientific insights in the field of tumor immunology into improved response to cancer immunotherapies.
At OREGA Biotech, we are translating years of basic research in the field of tumor immunology into novel immotherapeutic approaches to treat cancer. We specialize in the development of first-in-class monoclonal antibodies targeting novel immune checkpoints and regulators of the antitumoral immunity.
Our team focuses on the discovery and validation of novel targets that regulate the response to cancer immunotherapies. Our goal is to improve current anticancer strategies, response rates and patient survival. We rely on early partnerships with biotech and pharma companies to build our programs.
Our most advanced program, a humanized CD39 antibody licensed to Innate Pharma/AstraZeneca, is in phase 2 clinical trial in non small cell lung cancer.
Jeremy Bastid, CEO
Jeremy Bastid holds a PharmD degree and a PhD in oncology. He specialized in immuno-oncology and pediatric oncology. He performed research activities at the INSERM U590 in the Centre Léon-Bérard, Lyon and held several positions at the Hospices Civils de Lyon and at the Université Claude Bernard Lyon 1. He is R&D Director of OCTALFA (holding company) and Chief Development Officer of ORPHELIA Pharma, in charge of clinical and business development.
Gilles Alberici, Chairman
Gilles Alberici holds a PharmD degree and a PhD in Immunology. He founded and managed several biopharmaceutical and biotechnology companies in various therapeutic areas, notably immunosuppression and transplantation, acute leukemias and rare diseases. Gilles manages OCTALFA, a family-owned holding company specializing in Life Sciences, and the Dominique & Tom Alberici-Octalfa Corporate Foundation. He is Executive Chairman of ORPHELIA Pharma.
Nathalie Bonnefoy, Founder & CSO
Nathalie Bonnefoy, PhD in Immunology, is Research Director and team leader at INSERM 1194 and Deputy Director at the Institut de Recherche en Cancérologie de Montpellier. Her team focuses on studying the immune microenvironnement of tumors. Nathalie Bonnefoy is author of more than 80 scientific peer reviewed publications and 10 patents.
Armand Bensussan, Founder
Armand Bensussan, PhD, is director of the Skin Research Center and of INSERM 976 at Saint-Louis Hospital in Paris, France. He was the past president of the French society of immunology. His scientific contributions have been in the field of basic immunology and onco-dermatology. He is author of more than 300 scientific publications and 10 patents.
Jean-François Eliaou, Founder
Jean-François Eliaou, MD, PhD, is Professor of Medicine in Immunology. Head of the Department of Immunology at the University Hospital of Montpellier. He possesses recognized expertise in the field of Immunogenetics, Transplantation Immunology and autoimmune and chronic inflammatory diseases. He is author of more than 60 scientific publications.
Collaboration Agreement with Innate Pharma (CD39 antibody).
Second financing round.
License Agreement with Innate Pharma (CD39 antibody).
CD39 antibody program partnered with AstraZeneca.
First in human (phase 1), CD39 antibody.
Jeremy Bastid’s appointment as CEO.
Collaboration Agreement with Genmab (undisclosed target).
Phase 2 in lung cancer announced, CD39 antibody.
License Agreement with Genmab (undisclosed antibody program).